Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.

ABSTRACT: Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and nearly 1.6 million patients succumb to HIV each year. Several factors, including cross-species transmission and error-prone replication have resulted in extraordinary genetic diversity of HIV groups. One of these groups, known as group M (main) contains nine subtypes (A-D, F-H and J-K) and causes ~95% of all HIV infections. Most reported data on susceptibility and resistance to anti-HIV therapies are from subtype B HIV infections, which are prevalent in developed countries but account for only ~12% of all global HIV infections, whereas non-B subtype HIV infections that account for ~88% of all HIV infections are prevalent primarily in low and middle-income countries. Although the treatments fo

SUBMITTER: Singh K 

PROVIDER: S-EPMC4189038 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature